The decision marks the first time HMOs has been approved by China for use in infant formula.
IFF has announced that its 2′-fucosyllactose (2’-FL), human milk oligosaccharide (HMO) has achieved regulatory approval (NHC No. 8, 2023) in China for infant formula, follow-up formula, and formula for special medical purposes for infants. Citing data from Euromonitor, IFF explains that China has the largest milk formula segment worldwide, representing nearly 50% of the global market’s total retail value, and prior to this announcement, HMOs were not approved for use in infant formula in China.
“The infant formula industry has eagerly awaited the approval of 2’-FL in China, since it will allow producers to formulate a new generation of products for the early-life nutrition segment,” said Marcus Gliwitzki, global product manager, Health, IFF, in a press release “Today’s decision will help us better serve customers in all major markets and respond to the rising global demand for infant nutrition products.”
“We are thrilled to contribute to bringing infant formula closer to human milk,” added Klaas Illeghems, global strategic business unit leader, INFAT, HMO & Biosciences, Health, IFF. “This is our first HMO ingredient for the Chinese market, and we are committed to accelerate more of our high-quality HMOs to customers soon